earnings
confidence high
sentiment positive
materiality 0.75
Evolus Q2 revenue $66.9M (+36% YoY); raises FY2024 guidance to $260-270M; first positive non-GAAP operating income
Evolus, Inc.
2024-Q2 EPS reported
-$0.40
revenue$126,242,000
- Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.
- GAAP operating loss improved to $7.7M; first positive non-GAAP operating income of $1.1M.
- Raised full-year 2024 net revenue guidance to $260M-$270M (top end 34% YoY growth).
- PMA submitted to FDA for Evolysse Lift and Smooth fillers; approval and launch expected H2 2025.
- Added 770 new customer accounts; total ~14,000 since launch; reorder rate ~70%.